R.H. Bluestein & Co’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.2M | Sell |
27,389
-9,240
| -25% | -$449K | 0.07% | 80 |
|
|
2022
Q2 | $1.92M | Buy |
36,629
+10,875
| +42% | +$554K | 0.12% | 69 |
|
|
2022
Q1 | $1.33M | Sell |
25,754
-4,050
| -14% | -$210K | 0.06% | 85 |
|
|
2021
Q4 | $1.76M | Sell |
29,804
-7,112
| -19% | -$352K | 0.06% | 74 |
|
|
2021
Q3 | $1.59M | Buy |
36,916
+13,340
| +57% | +$591K | 0.06% | 74 |
|
|
2021
Q2 | $923K | Buy |
23,576
+5,985
| +34% | +$233K | 0.04% | 133 |
|
|
2021
Q1 | $637K | Sell |
17,591
-1,719
| -9% | -$61K | 0.03% | 169 |
|
|
2020
Q4 | $711K | Buy |
19,310
+21
| +0.1% | +$770 | 0.03% | 137 |
|
|
2020
Q3 | $672K | Hold |
19,289
| – | – | 0.03% | 125 |
|
|
2020
Q2 | $598K | Buy |
19,289
+738
| +4% | +$25.1K | 0.03% | 130 |
|
|
2020
Q1 | $574K | Buy |
18,551
+969
| +6% | +$33K | 0.05% | 107 |
|
|
2019
Q4 | $654K | Hold |
17,582
| – | – | 0.03% | 126 |
|
|
2019
Q3 | $599K | Buy |
17,582
+2,335
| +15% | +$84.9K | 0.03% | 128 |
|
|
2019
Q2 | $627K | Buy |
15,247
+458
| +3% | +$18.2K | 0.03% | 119 |
|
|
2019
Q1 | $596K | Sell |
14,789
-52
| -0.4% | -$2.08K | 0.03% | 111 |
|
|
2018
Q4 | $615K | Sell |
14,841
-1,692
| -10% | -$70.2K | 0.05% | 88 |
|
|
2018
Q3 | $691K | Sell |
16,533
-90
| -0.5% | -$3.46K | 0.03% | 119 |
|
|
2018
Q2 | $572K | Sell |
16,623
-1,354
| -8% | -$46.3K | 0.03% | 135 |
|
|
2018
Q1 | $605K | Sell |
17,977
-631,848
| -97% | -$21.7M | 0.03% | 130 |
|
|
2017
Q4 | $22.3M | Buy |
649,825
+20,007
| +3% | +$682K | 1.16% | 40 |
|
|
2017
Q3 | $21.3M | Sell |
629,818
-179,889
| -22% | -$5.78M | 1.17% | 34 |
|
|
2017
Q2 | $25.8M | Sell |
809,707
-61,122
| -7% | -$1.93M | 1.5% | 32 |
|
|
2017
Q1 | $28.3M | Sell |
870,829
-31,835
| -4% | -$1M | 1.69% | 29 |
|
|
2016
Q4 | $27.8M | Buy |
902,664
+384
| +0% | +$11.7K | 1.81% | 29 |
|
|
2016
Q3 | $29M | Buy |
902,280
+466,013
| +107% | +$15.6M | 1.91% | 29 |
|
|
2016
Q2 | $14.6M | Buy |
436,267
+416,675
| +2,127% | +$13.3M | 1.12% | 34 |
|
|
2016
Q1 | $551K | Sell |
19,592
-33,164
| -63% | -$947K | 0.04% | 118 |
|
|
2015
Q4 | $1.62M | Buy |
52,756
+31,960
| +154% | +$1.01M | 0.1% | 57 |
|
|
2015
Q3 | $620K | Sell |
20,796
-141
| -0.7% | -$4.52K | 0.04% | 109 |
|
|
2015
Q2 | $666K | Buy |
20,937
+596
| +3% | +$19.4K | 0.04% | 133 |
|
|
2015
Q1 | $671K | Buy |
20,341
+5,481
| +37% | +$174K | 0.04% | 126 |
|
|
2014
Q4 | $439K | Sell |
14,860
-454
| -3% | -$13K | 0.03% | 198 |
|
|
2014
Q3 | $430K | Sell |
15,314
-353
| -2% | -$9.91K | 0.03% | 216 |
|
|
2014
Q2 | $441K | Sell |
15,667
-1,195
| -7% | -$34.1K | 0.03% | 225 |
|
|
2014
Q1 | $514K | Sell |
16,862
-300,780
| -95% | -$8.97M | 0.03% | 186 |
|
|
2013
Q4 | $9.23M | Sell |
317,642
-69,358
| -18% | -$2.02M | 0.58% | 53 |
|
|
2013
Q3 | $10.5M | Buy |
387,000
+38,348
| +11% | +$1.04M | 0.75% | 47 |
|
|
2013
Q2 | $9.27M | Buy |
+348,652
| New | +$9.63M | 0.81% | 42 |
|
Other funds holding PFE
R.H. Bluestein & Co's PFE Position: Q3 2022 in Review
R.H. Bluestein & Co reduced its Pfizer (PFE) stake by 25% in Q3 2022, selling an estimated $449K and leaving 27,389 shares worth $1.2M. The position accounts for 0.07% of the portfolio, ranked #80.
R.H. Bluestein & Co first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $29M in Q3 2016. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- R.H. Bluestein & Co held 27,389 shares of Pfizer worth $1.2M as of Q3 2022.
- R.H. Bluestein & Co sold 9,240 Pfizer shares in Q3 2022, an estimated $449K.
- Pfizer made up 0.07% of R.H. Bluestein & Co's portfolio in Q3 2022, its #80 holding.
- R.H. Bluestein & Co first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- R.H. Bluestein & Co's Pfizer position peaked at $29M in Q3 2016.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.